University of Michigan presents multitargeted kinase inhibitor LP-182 for myelofibrosis
Aug. 22, 2022
In cancer, aberrant signaling pathways can evade therapy; activation of oncogenic PI3K and MAPK signaling has inspired researchers to develop molecularly targeted drugs, such as LP-182 (University of Michigan), a multitargeted kinase inhibitor that researchers have tested in vitro and in vivo for the treatment of myelofibrosis.